# Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

> **NCT03060720** · — · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 271 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03060720
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-24
- **Primary completion:** 2019-04-07
- **Final completion:** 2028-02
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03060720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03060720, "Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03060720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*